摘要
目的观察异帕米星联合头孢哌酮/舒巴坦治疗ICU泛耐药鲍曼不动杆菌肺部感染的临床疗效及安全性。方法 60例ICU泛耐药鲍曼不动杆菌肺部感染的重症患者随机分为异帕米星联合头孢哌酮/舒巴坦治疗组(A组)和对照组(B组,单纯应用头孢哌酮/舒巴坦),观察两组的临床疗效、细菌学疗效及肝肾功能指标的变化。结果异帕米星联合头孢哌酮/舒巴坦治疗组临床总有效率及细菌清除率明显高于对照组,部分临床生化指标好转,未出现肝肾功能指标恶化。结论异帕米星联合头孢哌酮/舒巴坦对ICU泛耐药鲍曼不动杆菌肺部感染具有良好的临床疗效,是一个值得推广的临床抗菌策略。
Abstract Objective To investigate the clinical efficacy and safety of Isepamicin combined with cefoperazone/sulbactam in the treatment of pulmonary infection of extensively drug - resistant Acinetobacter baumannii in ICU. Methods Sixty severe patients with pul- monary infection of extensively drug- resistant Acinetobacter baumannii in ICU were divided into the treatment group （group A, n = 30） treated with Isepamicin combined with cefoperazone/sulbaetam and the control group （group B, n = 30） treated with cefoperazone/sulbac- tam. The clinical efficacy, bacteriological efficacy, liver and kidney function were observed. Results The total clinical therapy effective rate and bacterial eradication rate of the treatment group were significantly higher than those of the control group（P 〈 0.05）. The clinical biochemical indicators in the treatment group were partly improved （ P 〈 0.05 ） and deterioration of liver and kidney function didnot occur. Conclusion Isepamicin combined with cefoperazone/sulbactam has a significant effect in the treatment of pulmonary infection of extensively drug -resistant Acinetobacter baumannii in ICU and can to be advocated.
出处
《医学研究杂志》
2011年第8期122-124,共3页
Journal of Medical Research
关键词
异帕米星
鲍曼不动杆菌
临床疗效
Isepamicin
Acinetobacter baumannii
Clinical efficacy
作者简介
通讯作者：林建东，电子信箱：Linjd@tom．com
